The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IACH Focus on Leukemia 2020 | Antibody-based therapy to treat AML: radioimmunoconjugates
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of antibody-based therapy in acute myeloid leukemia (AML). Antibody therapy has shown to be useful in AML as seen with gemtuzumab ozogamicin that has now been re-approved for adults with newly diagnosed CD33-positive AML and adults and children 2 years and older with relapsed or refractory CD33-positive AML. Other conjugates are in development, such as radioimmunoconjugates. One molecule of particular interest is Iomab-B, monoclonal antibody BC8, targeting CD45 linked to the radioisotope iodine-131. Iomab-B is currently being studied in the pivotal Phase 3 SIERRA (Study of Iomab-B in Relapsed or Refractory AML) trial (NCT02665065). This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
